{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.5","upperLimit":"88.3","value":"79.13"},{"groupId":"OG001","lowerLimit":"61.2","upperLimit":"89.5","value":"79.20"},{"groupId":"OG002","lowerLimit":"72.4","upperLimit":"96.7","value":"90.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.9","upperLimit":"83.6","value":"73.89"},{"groupId":"OG001","lowerLimit":"60.6","upperLimit":"88.3","value":"77.91"},{"groupId":"OG002","lowerLimit":"71.8","upperLimit":"95.4","value":"88.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \\>1% of BCR-ABL1IS. Progression to AP: ≥15% and \\<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \\<30% blasts) or \\<100\\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (i.e., participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Overall number of participants analyzed is the number of participants with MR2. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","timeFrame":"12 and 24 months after the first dose of study treatment","title":"Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24","type":"SECONDARY","unitOfMeasure":"percentage of participants"}